Masahiro Fukuoka, MD | Authors

Role of Topoisomerase I Inhibitors in Small-Cell Lung Cancer

July 01, 2001

Combination chemotherapy is the cornerstone of treatment that confers a meaningful survival benefit for patients with small-cell lung cancer. However, because there have been no major therapeutic advances for small-cell lung

State of the Art of Non-Small-Cell Lung Cancer in the New Millennium

March 03, 2001

Lung cancer is the leading cause of cancer death worldwide, with mortality rates in most developed countries ranging from 35 to 95 fatalities per 100,000 in men and 10 to 20 deaths per 100,000 in women.[1] Non-small-cell lung cancer is the most

Current Status of Irinotecan in Lung Cancer

January 01, 2001

Survival in lung cancer patients has not improved over the past 2 decades. Irinotecan (Camptosar, CPT-11), a semisynthetic analog of the quinoline-based alkaloid camptothecin, is one of several new drugs that have demonstrated promising activity in the treatment of lung cancer in recent years. This article gives a brief overview of the mechanism, development history, and current uses of this agent. [ONCOLOGY 15(Suppl 1):6-7, 2001]

Irinotecan in Small-Cell Lung Cancer-Japanese Trials

July 02, 2000

Irinotecan has appeared to have significant activity against previously treated and untreated small-cell lung cancer (SCLC). The major toxicities of irinotecan are neutropenia and diarrhea, although there is interpatient